BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36179506)

  • 1. Assessment of dependence potential and abuse liability of Δ
    Vanegas SO; Reck AM; Rodriguez CE; Marusich JA; Yassin O; Sotzing G; Wiley JL; Kinsey SG
    Drug Alcohol Depend; 2022 Nov; 240():109640. PubMed ID: 36179506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration.
    Falenski KW; Thorpe AJ; Schlosburg JE; Cravatt BF; Abdullah RA; Smith TH; Selley DE; Lichtman AH; Sim-Selley LJ
    Neuropsychopharmacology; 2010 Jul; 35(8):1775-87. PubMed ID: 20357755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced discriminative stimulus effects of Δ(9)-THC in the presence of cannabidiol and 8-OH-DPAT in rhesus monkeys.
    McMahon LR
    Drug Alcohol Depend; 2016 Aug; 165():87-93. PubMed ID: 27289270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Delta(9)-tetrahydrocannabinol in C57BL/6J mice.
    McMahon LR; Ginsburg BC; Lamb RJ
    Psychopharmacology (Berl); 2008 Jul; 198(4):487-95. PubMed ID: 17673980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel behavioral assays of spontaneous and precipitated THC withdrawal in mice.
    Trexler KR; Nass SR; Crowe MS; Gross JD; Jones MS; McKitrick AW; Siderovski DP; Kinsey SG
    Drug Alcohol Depend; 2018 Oct; 191():14-24. PubMed ID: 30071445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The short-acting synthetic cannabinoid AB-FUBINACA induces physical dependence in mice.
    Trexler KR; Vanegas SO; Poklis JL; Kinsey SG
    Drug Alcohol Depend; 2020 Sep; 214():108179. PubMed ID: 32688070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol.
    DeLong GT; Wolf CE; Poklis A; Lichtman AH
    Drug Alcohol Depend; 2010 Nov; 112(1-2):126-33. PubMed ID: 20619971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential disruption of response alternation by precipitated Δ
    Eckard ML; Kinsey SG
    Pharmacol Biochem Behav; 2024 Mar; 236():173718. PubMed ID: 38272272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist.
    Tai S; Nikas SP; Shukla VG; Vemuri K; Makriyannis A; Järbe TU
    Psychopharmacology (Berl); 2015 Aug; 232(15):2751-61. PubMed ID: 25772338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel 3-substituted rimonabant analogues lack Δ(9) -tetrahydrocannabinol-like abuse-related behavioural effects in mice.
    Walentiny D; Vann R; Mahadevan A; Kottani R; Gujjar R; Wiley J
    Br J Pharmacol; 2013 May; 169(1):10-20. PubMed ID: 23297801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JWH-018 and JWH-073: Δ⁹-tetrahydrocannabinol-like discriminative stimulus effects in monkeys.
    Ginsburg BC; Schulze DR; Hruba L; McMahon LR
    J Pharmacol Exp Ther; 2012 Jan; 340(1):37-45. PubMed ID: 21965552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids.
    Janoyan JJ; Crim JL; Darmani NA
    Pharmacol Biochem Behav; 2002; 71(1-2):155-62. PubMed ID: 11812518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic Δ⁹-tetrahydrocannabinol treatment in rhesus monkeys: differential tolerance and cross-tolerance among cannabinoids.
    McMahon LR
    Br J Pharmacol; 2011 Mar; 162(5):1060-73. PubMed ID: 21091643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of cannabimimetic effects of selected minor cannabinoids and Terpenoids in mice.
    Wiley JL; Marusich JA; Blough BE; Namjoshi O; Brackeen M; Akinfiresoye LR; Walker TD; Prioleau C; Barrus DG; Gamage TF
    Prog Neuropsychopharmacol Biol Psychiatry; 2024 Jun; 132():110984. PubMed ID: 38417478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological characterization of repeated administration of the first generation abused synthetic cannabinoid CP47,497.
    Grim TW; Samano KL; Ignatowska-Jankowska B; Tao Q; Sim-Selly LJ; Selley DE; Wise LE; Poklis A; Lichtman AH
    J Basic Clin Physiol Pharmacol; 2016 May; 27(3):217-28. PubMed ID: 27149200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CB
    Trexler KR; Eckard ML; Kinsey SG
    Pharmacol Biochem Behav; 2019 Feb; 177():27-33. PubMed ID: 30597181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rimonabant-induced Delta9-tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs.
    Stewart JL; McMahon LR
    J Pharmacol Exp Ther; 2010 Jul; 334(1):347-56. PubMed ID: 20375197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
    McMahon LR; Koek W
    Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerance and cross-tolerance to cannabinoids in mice: schedule-controlled responding and hypothermia.
    Singh H; Schulze DR; McMahon LR
    Psychopharmacology (Berl); 2011 Jun; 215(4):665-75. PubMed ID: 21246187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.
    McMahon LR
    Psychopharmacology (Berl); 2006 Oct; 188(3):306-14. PubMed ID: 16953389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.